Literature DB >> 21080155

Towards a sensible comprehension of severe community-acquired pneumonia.

Santiago Ewig1, Mark Woodhead, Antoni Torres.   

Abstract

Four different rules have been suggested and validated for intensive care unit (ICU) admission for community-acquired pneumonia: modified American Thoracic Society (ATS) rule, Infectious Diseases Society of America (IDSA)/ATS rule, España rule, and SMART-COP. Their performance varies, with sensitivity of around 70% and specificity of around 80-90%. Only negative predictive values are consistently high. Critical methodological issues include the appropriate reference for derivation, the populations studied, the variables included, and the time course of pneumonia. Severe community-acquired pneumonia (SCAP) may evolve because of acute respiratory failure or/and severe sepsis/septic shock. Pneumonia-related complications and decompensated comorbidities may be additional or independent reasons for a severe course. All variables included in predictive rules relate to the two principal reasons for SCAP. However, taken as major criteria, they are of little value for clinical assessment. Instead, a limited set of minor criteria reflecting severity seems appropriate. However, predictive rules may not meet principal needs of severity assessment because of failure in sensitivity, ignorance of the potential contribution of complications or decompensated comorbidity to pneumonia severity, and poor sensitivity for the lower extreme in the spectrum of severe pneumonia, i.e., patients at risk of SCAP. We therefore advocate an approach that refers to the evaluation of the need for intensified treatment rather than ICU, based on a set of minor criteria and sensitive to the dynamic nature of pneumonia. Intensified treatment such as monitoring and treatment of acute respiratory failure or/and severe sepsis/septic shock is thought to improve management and possibly outcomes by setting the focus on both patients with severity criteria at admission and those at risk for SCAP.

Entities:  

Mesh:

Year:  2010        PMID: 21080155     DOI: 10.1007/s00134-010-2077-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  33 in total

1.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

2.  Against misleading predictions for severe community-acquired pneumonia.

Authors:  Santiago Ewig
Journal:  Am J Respir Crit Care Med       Date:  2007-02-01       Impact factor: 21.405

3.  Development and validation of a clinical prediction rule for severe community-acquired pneumonia.

Authors:  Pedro P España; Alberto Capelastegui; Inmaculada Gorordo; Cristobal Esteban; Mikel Oribe; Miguel Ortega; Amaia Bilbao; José M Quintana
Journal:  Am J Respir Crit Care Med       Date:  2006-09-14       Impact factor: 21.405

4.  CRB-65 for the assessment of pneumonia severity: who could ask for more?

Authors:  Santiago Ewig; Tobias Welte
Journal:  Thorax       Date:  2008-08       Impact factor: 9.139

5.  The impact of a delay in intensive care unit admission for community-acquired pneumonia.

Authors:  J Phua; W J Ngerng; T K Lim
Journal:  Eur Respir J       Date:  2010-02-25       Impact factor: 16.671

6.  Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group.

Authors:  B J Marston; J F Plouffe; T M File; B A Hackman; S J Salstrom; H B Lipman; M S Kolczak; R F Breiman
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

Review 7.  Lower respiratory tract infection and pneumonia in the community.

Authors:  J Macfarlane
Journal:  Semin Respir Infect       Date:  1999-06

8.  Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia.

Authors:  Samuel M Brown; Barbara E Jones; Al R Jephson; Nathan C Dean
Journal:  Crit Care Med       Date:  2009-12       Impact factor: 7.598

9.  Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae.

Authors:  Paschalina Kontou; Joseph L Kuti; David P Nicolau
Journal:  Am J Emerg Med       Date:  2009-10       Impact factor: 2.469

10.  New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality.

Authors:  S Ewig; N Birkner; R Strauss; E Schaefer; J Pauletzki; H Bischoff; P Schraeder; T Welte; G Hoeffken
Journal:  Thorax       Date:  2009-05-18       Impact factor: 9.139

View more
  19 in total

Review 1.  Community-acquired pneumonia related to intracellular pathogens.

Authors:  Catia Cillóniz; Antoni Torres; Michael Niederman; Menno van der Eerden; James Chalmers; Tobias Welte; Francesco Blasi
Journal:  Intensive Care Med       Date:  2016-06-08       Impact factor: 17.440

2.  Hypocapnia and hypercapnia are predictors for ICU admission and mortality in hospitalized patients with community-acquired pneumonia.

Authors:  Elena Laserna; Oriol Sibila; Patrick R Aguilar; Eric M Mortensen; Antonio Anzueto; Jose M Blanquer; Francisco Sanz; Jordi Rello; Pedro J Marcos; Maria I Velez; Nivin Aziz; Marcos I Restrepo
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

Review 3.  Long-term prognosis in community-acquired pneumonia.

Authors:  Marcos I Restrepo; Paola Faverio; Antonio Anzueto
Journal:  Curr Opin Infect Dis       Date:  2013-04       Impact factor: 4.915

4.  How to derive and validate clinical prediction models for use in intensive care medicine.

Authors:  José Labarère; Bertrand Renaud; Renaud Bertrand; Michael J Fine
Journal:  Intensive Care Med       Date:  2014-02-26       Impact factor: 17.440

Review 5.  The management of community-acquired pneumonia in the elderly.

Authors:  Paola Faverio; Stefano Aliberti; Giuseppe Bellelli; Giulia Suigo; Sara Lonni; Alberto Pesci; Marcos I Restrepo
Journal:  Eur J Intern Med       Date:  2013-12-17       Impact factor: 4.487

Review 6.  Year in review in Intensive Care Medicine 2011. II. Cardiovascular, infections, pneumonia and sepsis, critical care organization and outcome, education, ultrasonography, metabolism and coagulation.

Authors:  Massimo Antonelli; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Daniel De Backer; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2012-01-20       Impact factor: 17.440

7.  Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study.

Authors:  Martin Kolditz; Gert Höffken; Peter Martus; Gernot Rohde; Hartwig Schütte; Robert Bals; Norbert Suttorp; Mathias W Pletz
Journal:  BMC Infect Dis       Date:  2012-04-13       Impact factor: 3.090

8.  Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis.

Authors:  Catia Cillóniz; Santiago Ewig; Miquel Ferrer; Eva Polverino; Albert Gabarrús; Jorge Puig de la Bellacasa; Josep Mensa; Antoni Torres
Journal:  Crit Care       Date:  2011-09-14       Impact factor: 9.097

9.  Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia.

Authors:  Ilija Andrijevic; Jovan Matijasevic; Ljiljana Andrijevic; Tomi Kovacevic; Bojan Zaric
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

10.  Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years.

Authors:  Reiko Sato; Gabriel Gomez Rey; Stephanie Nelson; Brett Pinsky
Journal:  Appl Health Econ Health Policy       Date:  2013-06       Impact factor: 2.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.